What were the main drivers of Johnson & Johnson's sales performance in this quarter?

Sales performance was mixed across segments. The Pharmaceutical segment saw growth driven by REMICADE® and other products, and the Medical Devices and Diagnostics segment also showed growth. However, the Consumer segment experienced a significant decline due to recalls of OTC products and manufacturing suspensions, which negatively impacted overall sales.

How did the Consumer segment issues affect the company's overall financial results?

The substantial decline in the Consumer segment's sales and operating profit significantly impacted the company's consolidated results. Management is actively addressing these issues through recalls, remediation efforts, and action plans submitted to the FDA, with projected improvements expected in 2011.

What is the outlook for the Pharmaceutical segment, considering the competitive landscape?

The Pharmaceutical segment remains a strong performer, with continued growth in REMICADE® and other products. However, the company acknowledges increasing competition, including from its own immunology products, and the impact of generic drug entries for products like LEVAQUIN® and TOPAMAX® as their market exclusivity expires.

How is the company managing its cash and debt?

Johnson & Johnson generated strong operating cash flow of $12.6 billion for the nine months ended October 3, 2010. The company used cash for dividends to shareholders, debt retirement, and share repurchases, while also increasing borrowings to capitalize on favorable market conditions. The company anticipates sufficient resources to fund its operating needs.

JNJ 10-Q Filed Nov 10, 2010

Summary

Johnson & Johnson (JNJ) reported solid financial results for the fiscal third quarter ending October 3, 2010. Total sales remained relatively flat year-over-year at $14.98 billion, with a slight decrease of 0.7%, impacted by currency fluctuations. However, operational growth was positive, indicating underlying business strength. Net earnings saw a modest increase to $3.42 billion, up from $3.35 billion in the prior year's comparable quarter, resulting in diluted earnings per share of $1.23, an increase from $1.20. The company's diverse business segments showed varied performance. The Pharmaceutical segment reported a 4.7% sales increase, driven by strong performance in REMICADE® and other key drugs. The Medical Devices and Diagnostics segment also experienced growth, with a 1.3% increase in sales, supported by DePuy and Ethicon franchises. Conversely, the Consumer segment saw a notable 10.6% sales decline, primarily due to recalls and manufacturing issues impacting its Over-the-Counter (OTC) products, although proactive measures are being taken to address these challenges.

Key Highlights

1Total sales for the quarter were $14.98 billion, a slight decrease of 0.7% year-over-year, with operational growth offsetting currency headwinds.
2Net earnings increased to $3.42 billion, translating to diluted EPS of $1.23, up from $1.20 in the prior year's quarter.
3The Pharmaceutical segment demonstrated robust growth with sales up 4.7%, boosted by key products like REMICADE®.
4The Medical Devices and Diagnostics segment reported a 1.3% sales increase, showcasing resilience and growth in key franchises.
5The Consumer segment faced a significant 10.6% sales decline, largely attributed to ongoing issues with OTC product recalls and manufacturing disruptions.
6The company generated strong operating cash flow of $12.6 billion for the nine months ended October 3, 2010.
7Johnson & Johnson declared and paid a regular quarterly cash dividend of $0.540 per share, indicating a continued commitment to shareholder returns.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Oct 3, 2010

Summary

Key Highlights

Frequently Asked Questions